BioLife Solutions Inc (NASDAQ:BLFS) shares hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $12.00 and last traded at $11.64, with a volume of 15019 shares trading hands. The stock had previously closed at $11.60.

Several research analysts recently issued reports on the company. Maxim Group set a $8.00 target price on BioLife Solutions and gave the company a “buy” rating in a research report on Friday, March 9th. B. Riley assumed coverage on BioLife Solutions in a report on Thursday, June 7th. They issued a “buy” rating and a $14.00 price objective on the stock. ValuEngine raised BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Friday, May 4th. Finally, Northland Securities assumed coverage on BioLife Solutions in a report on Monday, March 12th. They issued an “outperform” rating on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $10.33.

The firm has a market cap of $151.64 million, a price-to-earnings ratio of -55.09 and a beta of 0.40.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 10th. The medical equipment provider reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The firm had revenue of $3.82 million during the quarter, compared to analyst estimates of $3.81 million. BioLife Solutions had a negative net margin of 13.17% and a negative return on equity of 18.99%. analysts expect that BioLife Solutions Inc will post -0.03 EPS for the current fiscal year.

In other news, Director Joseph C. Schick sold 6,858 shares of the company’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $10.07, for a total value of $69,060.06. Following the sale, the director now owns 14,765 shares in the company, valued at $148,683.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Girschweiler sold 1,025,000 shares of the company’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $5.26, for a total value of $5,391,500.00. The disclosure for this sale can be found here. Insiders sold 1,091,938 shares of company stock worth $5,998,818 in the last 90 days. Company insiders own 38.50% of the company’s stock.

An institutional investor recently raised its position in BioLife Solutions stock. Millennium Management LLC lifted its stake in BioLife Solutions Inc (NASDAQ:BLFS) by 901.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 182,550 shares of the medical equipment provider’s stock after buying an additional 164,324 shares during the quarter. Millennium Management LLC owned approximately 1.30% of BioLife Solutions worth $1,095,000 as of its most recent SEC filing. Institutional investors own 11.90% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.